Evidence map›Paper›PMID 42278563›Full record

ArticleInternational journal of molecular sciences2026

Özlem Türksoy Terzioğlu, Gökhan Terzioğlu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Özlem Türksoy TerzioğluDepartment of Molecular Biology and Genetics, Hamidiye Institute of Health Sciences, University of Health Sciences, Istanbul 34899, Türkiye.
Gökhan TerzioğluDepartment of Medical Biology, Hamidiye International School of Medicine, University of Health Sciences, Istanbul 34899, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance remains a major obstacle in gastric cancer therapy and is frequently associated with aggressive phenotypes. Although

Indexed as

ATP Binding Cassette Transporter, Subfamily G, Member 2Drug Resistance, MultipleDrug Resistance, NeoplasmMAP Kinase Signaling SystemNeoplasm ProteinsStomach NeoplasmsAntineoplastic AgentsApoptosisCell Line, TumorCisplatinFluorouracilGene Expression Regulation, NeoplasticHumansPaclitaxelPhenotypeABCG2 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily G, Member 2CisplatinFluorouracilNeoplasm ProteinsPaclitaxelABCG2epithelial–mesenchymal transitionERK signalinggastric cancermultidrug resistancepaclitaxel resistancestemness

Identifiers

PMID42278563
PMCPMC13256579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.